CN101969970B - 用抗体-药物偶联物联合治疗 - Google Patents
用抗体-药物偶联物联合治疗 Download PDFInfo
- Publication number
- CN101969970B CN101969970B CN200880111297.1A CN200880111297A CN101969970B CN 101969970 B CN101969970 B CN 101969970B CN 200880111297 A CN200880111297 A CN 200880111297A CN 101969970 B CN101969970 B CN 101969970B
- Authority
- CN
- China
- Prior art keywords
- antibody
- alkyl
- thiazolinyl
- alkynyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(*)NC(C(*)NC)=O Chemical compound CCC(*)NC(C(*)NC)=O 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97959407P | 2007-10-12 | 2007-10-12 | |
| US60/979,594 | 2007-10-12 | ||
| US2766808P | 2008-02-11 | 2008-02-11 | |
| US61/027,668 | 2008-02-11 | ||
| US4064108P | 2008-03-28 | 2008-03-28 | |
| US61/040,641 | 2008-03-28 | ||
| PCT/US2008/079224 WO2009048967A1 (en) | 2007-10-12 | 2008-10-08 | Combination therapy with antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101969970A CN101969970A (zh) | 2011-02-09 |
| CN101969970B true CN101969970B (zh) | 2014-10-15 |
Family
ID=40549535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880111297.1A Active CN101969970B (zh) | 2007-10-12 | 2008-10-08 | 用抗体-药物偶联物联合治疗 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8263083B2 (https=) |
| EP (1) | EP2211885B1 (https=) |
| JP (1) | JP5485897B2 (https=) |
| KR (1) | KR101641345B1 (https=) |
| CN (1) | CN101969970B (https=) |
| AU (1) | AU2008310908B2 (https=) |
| CA (1) | CA2699090C (https=) |
| EA (1) | EA020696B1 (https=) |
| IL (1) | IL204851A (https=) |
| MX (1) | MX2010003977A (https=) |
| NZ (1) | NZ584552A (https=) |
| WO (1) | WO2009048967A1 (https=) |
| ZA (1) | ZA201002428B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| DK2474557T3 (da) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
| NZ583318A (en) | 2007-07-16 | 2012-07-27 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| CN101969970B (zh) | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
| SG187517A1 (en) | 2008-01-31 | 2013-02-28 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| CA3159253A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| US8758758B1 (en) * | 2010-01-08 | 2014-06-24 | Seattle Genetics, Inc. | Post-relapse treatment of CD30 expressing lymphomas |
| AU2011213609B2 (en) * | 2010-02-08 | 2016-11-03 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
| AU2011316917B2 (en) * | 2010-10-22 | 2016-02-25 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
| CA2848520C (en) | 2011-09-29 | 2019-11-26 | Seattle Genetics, Inc. | Intact mass determination of protein conjugated agent compounds |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| MY168297A (en) | 2011-11-17 | 2018-10-23 | Pfizer | Cytotoxic Peptides and Antibody Drug Conjugates Thereof |
| EP3575794A1 (en) * | 2012-02-10 | 2019-12-04 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
| HK1214282A1 (zh) | 2012-11-07 | 2016-07-22 | 辉瑞公司 | 抗-notch3抗体及抗体-药物缀合物 |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| PT3262071T (pt) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
| AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| EP3694559A2 (en) * | 2017-10-11 | 2020-08-19 | Seattle Genetics, Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
| MA50369A (fr) * | 2017-10-13 | 2020-08-19 | Seattle Genetics Inc | Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CA3094313A1 (en) * | 2018-04-06 | 2019-10-10 | Seattle Genetics, Inc. | Camptothecin peptide conjugates |
| WO2019217455A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| TWI861039B (zh) | 2018-12-21 | 2024-11-11 | 瑞士商赫孚孟拉羅股份公司 | 靶向腫瘤之促效cd28抗原結合分子 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| AU2020356955A1 (en) * | 2019-10-04 | 2022-04-14 | Seagen Inc. | Camptothecin peptide conjugates |
| MX2022009389A (es) * | 2020-01-31 | 2022-10-13 | Seagen Inc | Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de linfoma no hodgkin. |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| CN119490595B (zh) * | 2023-08-15 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗免疫球蛋白e的抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5165922A (en) * | 1990-05-22 | 1992-11-24 | Bristol-Myers Squibb Company | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| HUE035853T2 (en) * | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| WO2007044616A2 (en) * | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| US8257706B2 (en) * | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
| WO2008103916A2 (en) | 2007-02-23 | 2008-08-28 | The Trustees Of Columbia Univeristy In The City Of New York | Compositions and methods for treating cancer or a neurotrophic disorder |
| CN101969970B (zh) | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
-
2008
- 2008-10-08 CN CN200880111297.1A patent/CN101969970B/zh active Active
- 2008-10-08 EA EA201070463A patent/EA020696B1/ru unknown
- 2008-10-08 US US12/681,599 patent/US8263083B2/en active Active
- 2008-10-08 EP EP08837451.7A patent/EP2211885B1/en active Active
- 2008-10-08 KR KR1020107008660A patent/KR101641345B1/ko active Active
- 2008-10-08 CA CA2699090A patent/CA2699090C/en active Active
- 2008-10-08 WO PCT/US2008/079224 patent/WO2009048967A1/en not_active Ceased
- 2008-10-08 JP JP2010529007A patent/JP5485897B2/ja not_active Expired - Fee Related
- 2008-10-08 MX MX2010003977A patent/MX2010003977A/es active IP Right Grant
- 2008-10-08 NZ NZ584552A patent/NZ584552A/en unknown
- 2008-10-08 AU AU2008310908A patent/AU2008310908B2/en not_active Ceased
-
2010
- 2010-04-06 IL IL204851A patent/IL204851A/en active IP Right Grant
- 2010-04-07 ZA ZA2010/02428A patent/ZA201002428B/en unknown
-
2012
- 2012-08-13 US US13/571,313 patent/US8470329B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Anti-CD30 antibody-based therapy;Koon HB;《current opinion in oncology》;20001130;第12卷(第6期);588-593 * |
| CD30 Antigen, a Marker for Hodgkin’s Lymphoma,Is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF;Craig A S;《cell》;19930702;第73卷;1349-1360 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US8263083B2 (en) | 2012-09-11 |
| AU2008310908B2 (en) | 2014-01-09 |
| HK1151727A1 (zh) | 2012-02-10 |
| EP2211885B1 (en) | 2015-07-29 |
| EA020696B1 (ru) | 2015-01-30 |
| IL204851A (en) | 2016-08-31 |
| WO2009048967A1 (en) | 2009-04-16 |
| EP2211885A4 (en) | 2012-09-26 |
| AU2008310908A1 (en) | 2009-04-16 |
| MX2010003977A (es) | 2010-04-30 |
| NZ584552A (en) | 2012-07-27 |
| CA2699090A1 (en) | 2009-04-16 |
| US20100215671A1 (en) | 2010-08-26 |
| JP5485897B2 (ja) | 2014-05-07 |
| CA2699090C (en) | 2016-02-02 |
| ZA201002428B (en) | 2011-06-29 |
| EP2211885A1 (en) | 2010-08-04 |
| KR20100087288A (ko) | 2010-08-04 |
| CN101969970A (zh) | 2011-02-09 |
| EA201070463A1 (ru) | 2010-10-29 |
| IL204851A0 (en) | 2010-11-30 |
| US20130022627A1 (en) | 2013-01-24 |
| US8470329B2 (en) | 2013-06-25 |
| KR101641345B1 (ko) | 2016-07-20 |
| JP2011500582A (ja) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101969970B (zh) | 用抗体-药物偶联物联合治疗 | |
| US20230033859A1 (en) | Cd19 binding agents and uses thereof | |
| CN106563128B (zh) | 以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途 | |
| US20110070248A1 (en) | Dr5 ligand drug conjugates | |
| US20130280282A1 (en) | Dr5 ligand drug conjugates | |
| US20080317747A1 (en) | Recombinant anti-cd30 antibodies and uses thereof | |
| US20070258987A1 (en) | Recombinant Anti-Cd30 Antibodies and Uses Thereof | |
| TWI873167B (zh) | 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症 | |
| CN112189020A (zh) | 包含微管蛋白破坏剂的抗体药物缀合物用于治疗实体瘤的用途 | |
| CN110352074B (zh) | 用于偶联的半胱氨酸突变抗体 | |
| US20230025600A1 (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| HK1151727B (en) | Combination therapy with antibody-drug conjugates | |
| EA052186B1 (ru) | Маркеры для применения в способах лечения рака с помощью конъюгатов антитело-лекарственное средство (adc) | |
| HK40044344A (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1151727 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1151727 Country of ref document: HK |